

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

HE 20.4210.782 / SUPP. 6

CUMULATIVE SUPPLEMENT 6 AUG '82 - FEB '83

The University
of Michigan
Pharmacy
Library


MAY 16 1983
MEDICAL
LIBRARY

SERIAL

PHARMACY
AM 308
• R653
3rd ed.
Suppl. 3

REFERENCE

ALL INFORMATION
DOES NOT CIRCULATE



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
3RD EDITION

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

UNIVERSITY OF MICHIGAN
LIBRARIES

MAY 4 1983

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

DEPOSITED BY THE
UNITED STATES OF AMERICA

UNITED STATES OF AMERICA
SENT BY POSTAL SERVICE

1914

RECEIVED BY THE
LIBRARY OF THE
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (◊) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. INDICES AND ABBREVIATIONS:

STANDARD TERMS:

Added Route of Administration: INTRAPERITONEAL

B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month and the past two quarters.

- C. APPLICANT (NAME) CHANGES Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
NATCON CHEMICAL CO INC	NATCON CORPORATION	NATCON
ENDO LABORATORIES INC SUB	DUPONT PHARMACEUTICALS/	
EI DUPONT DE NEMOURS AND	EI DU PONT DE NEMOURS	
CO INC	AND CO INC	DUPONT PHARMS/DUPONT
WESTERN RESEARCH	PHARMACEUTICAL BASICS	
LABORATORIES INC	INC	PHARM BASICS

The reader should consult this special list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 3rd Edition, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '82 (BASELINE)	OCT '82	JAN '83
DRUG PRODUCTS LISTED	6303	6401	6488
SINGLE SOURCE	1885 (30%)	1899 (29.7%)	1910 (29.4%)
MULTISOURCE (1)	4418 (70%)	4502 (70.3%)	4578 (70.5%)
THERAPEUTICALLY EQUIVALENT	3456 (54.8%)	3533 (55.2%)	3610 (55.6%)
NOT THERAPEUTICALLY EQUIVALENT	954 (15.1%)	960 (15.0%)	959 (14.8%)
EXCEPTIONS (2)	8 (0.1%)	9 (0.1%)	9 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	8	18
NUMBER OF APPLICANTS	303	302	308

B. ACTIVITY FOR SUPPLEMENT NUMBER 6 AND CUMULATIVE SINCE JANUARY '83

	FEB '83	CUMULATIVE
DRUG PRODUCTS ADDED:	33	33
NEWLY APPROVED	33	33
DESI EFFECTIVE	0	0
REMARKETED	0	0
DRUG PRODUCTS REMOVED:	6	6
WITHDRAWN APPROVAL	0	0
RX TO OTC SWITCH	0	0
DISCONTINUED MARKETING	6	6
NET GAIN IN DRUG PRODUCTS	27	27
SINGLE SOURCE PRODUCTS APPROVED	8	8
MULTISOURCE DRUG PRODUCTS APPROVED	25	25
NEW MOLECULAR ENTITIES APPROVED:	3	3
AS THE ENTITY	2	2
AS A SALT, ESTER OR DERIVATIVE	1	1
OF THE ENTITY	1	1

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

DRUG PRODUCT LIST

CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '82 - FEBRUARY '83

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL
/CODEINE, ASPIRIN, APAP FORMULA NO. 4/
/FIRST TEXAS SCHERER/ 150MG; 250MG; 500MG/

/ALUMINUM CHLORHYDRATE ALLANTOINATE; PREDNISOLONE/ (PAGE 3-5)

/CREAM; TOPICAL/
/METI-DERM/
/SCHERING/ 0.25%; 0.5% /

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA GENERIC PHARMS/IVY 300MG; 300MG

/AA/ ACETAMINOPHEN W/ CODEINE PHOSPHATE

/CARBICK/SM CARBICK/ 325MG; 500MG/

/ALUMINUM NICOTINATE/ (PAGE 3-5)

/TABLET; ORAL/
/NICALEX/
/MERRELL POW/POW CHEN/ 625MG/

AMINO ACIDS (PAGE 3-6)ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL

TALACEN

STERLING DRUG 650MG; EQ 25MG BASEX

ACETAZOLAMIDE (PAGE 3-3)

TABLET; ORAL

ACETAZOLAMIDE

AB ASCOT HOSP PHARMS 250MGX

AMINOACETIC ACID (PAGE 3-7)ACYCLOVIR SODIUM (PAGE 3-4)

INJECTABLE; INJECTION

ZOVIRAX

BURROUGHS WELLCOME EQ 500MG BASE/VIALX

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

/AM HCGAM/AM HOSP/ 1.5GM/100ML/

GLYCINE 1.5% IN PLASTIC CONTAINER

/AM HCGAM/AM HOSP 1.5GM/100ML/

> DLT > AT/

> ADD > AT

ALBUTEROL SULFATE (PAGE 3-4)

SYRUP; ORAL

PROVENTIL

SCHERING

EQ 2MG BASE/5MLX

AMINOCAPROIC ACID (PAGE 3-7)

INJECTABLE; INJECTION

AMTCAR

AP LEDERLE PARENTERALS 250MG/ML

AMINOCAPROIC ACID

AP ELKINS-SINN/AHROBINS 250MG/MLX

ALCLOMETASONE DIPROPIONATE (PAGE 3-5)

CREAM; TOPICAL

VADERM

SCHERING

0.052X

OINTMENT; TOPICAL

VADERM

SCHERING

0.052X

AMINOPHYLLINE (PAGE 3-8)

SUPPOSITORY; RECTAL

TRUPHYLLINE

G AND W LABORATORIES 500MGX

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
(PAGE 3-18)

ointment; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN
 BYK-GULDEN 400 UNITS/GM; EQ 3.5MG BASE/GM;
 10,000 UNITS/GM
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
 PHARMAFAIR 400 UNITS/GM; EQ 3.5MG BASE/GM;
 10,000 UNITS/GM

AI
 AI
 AI
 AI

BETAMETHASONE DIPROPIONATE (PAGE 3-20)

cream; TOPICAL
 DIPROSONE
 SCHERING /EQ 0.5MG BASE/GM/
 EQ 0.05% BASE
 LOTION; TOPICAL
 DIPROSONE
 SCHERING /EQ 0.5MG BASE/GM/
 EQ 0.05% BASE
 OINTMENT; TOPICAL
 DIPROSONE
 SCHERING /EQ 0.5MG BASE/GM/
 EQ 0.05% BASE

BETAMETHASONE VALERATE (PAGE 3-20)

/AEROSOL; TOPICAL/
 VALISONE/
 SCHERING /0.15%/
 cream; TOPICAL
 VALISONE
 SCHERING /0.01%/
 EQ 0.01% BASE
 EQ 0.1% BASE

LOTION; TOPICAL
 VALISONE
 SCHERING /0.1%/
 EQ 0.1% BASE

ointment; TOPICAL
 VALISONE
 SCHERING /0.1%/
 EQ 0.1% BASE

BROMPHENIRAMINE MALEATE (PAGE 3-21)

ELIXIR; ORAL
 BROWNAY
 AA BAY LABORATORIES 2MG/5ML
 /COTTAGE/
 /AA/ /CORP. LABORATORIES/ 2MG/5ML/

> ADD > BUMETANIDE (PAGE 3-22)
 > ADD > INJECTABLE; INJECTION
 > ADD > BUMEX
 > ADD > HOFFMANN-LA ROCHE 0.25MG/ML
 > ADD > TABLET; ORAL
 > ADD > BUMEX
 > ADD > HOFFMANN-LA ROCHE 0.5MG
 1MG

BUTABARBITAL SODIUM (PAGE 3-23)

ELIXIR; ORAL
 BUTISOL SODIUM
 /AA/ /MCNEIL LABORATORIES/ 30MG/5ML/
 AA WALLACE LABS/C-W 30MG/5ML

BUTAPERAZINE MALEATE (PAGE 3-23)

/TABLET; ORAL/
 /REPOISE/
 /AN. ROBINS/ /EQ 10MG BASE/
 /EQ 25MG BASE/

CAFFEINE; CARISOPRODOL; PHENACETIN (PAGE 3-24)

TABLET; ORAL
 CARISOPRODOL COMPOUND
 AB DANBURY PHARMACAL 32MG; 200MG; 160MG

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-25)

/INJECTABLE; INJECTION/
 SOLUTION; INTRAPERITONEAL
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 TRAVENOL LABS 25.7MG/100ML; 1.5GH/100ML;
 5.0MG/100ML; 53MG/100ML; 448MG/100ML
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 TRAVENOL LABS 25.7MG/100ML; 2.5GH/100ML;
 5.0MG/100ML; 53MG/100ML; 448MG/100ML
 AI
 AI
 AI
 AI

CHLOROQUINE PHOSPHATE (PAGE 3-33)

TABLET; ORAL

ARALEN

AA WINTHROP LABS/STERL EQ 300MG BASE
 CHLOROQUINE PHOSPHATE
 AA DANBURY PHARMACAL EQ 150MG BASE
 AA EQ 300MG BASE

CHLOROTHIAZIDE (PAGE 3-33)

TABLET; ORAL

CHLOROTHIAZIDE

AB SOLAR PHARMACEUTICAL 500MG
 /AB/ /FEDERAL PHARMACAL/ /250MG/
 AB LEMMON 250MG

CHLORPHENIRAMINE MALEATE (PAGE 3-34)

SYRUP; ORAL

/AA/ /MYSTREY/
 /AA/ /BOYAN PHARMS/ /2MG/5ML/

CHLORPROMAZINE HYDROCHLORIDE (PAGE 3-35)

TABLET; ORAL

CHLORPROMAZINE HCL

BP VANGARD LABS/TMM 10MG
 BP WEST-NARD 10MG
 BP 25MG
 BP 50MG
 BP 100MG
 BP 200MG

CHLORTHALIDONE (PAGE 3-37)

TABLET; ORAL

CHLORTHALIDONE

AB ASCOT HOSP PHARMS 25MG
 AB 50MG
 AB PARKE-DAVIS/N-L 25MG
 AB 50MG
 AB SUPERPHARM 25MG
 AB 50MG
 AB /VANGARD LABS/TMM/ /25MG/
 AB VANGARD LABS/TMM 25MG
 AB THALITONE
 AB BOEHRINGER INGELHEIM 25MG

CHLORZOXAZONE (PAGE 3-37)

TABLET; ORAL

CHLORZOXAZONE

AA CHELSEA LABORATORIES 250MG

CHYTHOPAPAIN (PAGE 3-37)

INJECTABLE; INJECTION

CHYMODIACTIN
 SMITH LABORATORIES 10,000 UNITS/VIAL

CYCLOPIROX OLAMINE (PAGE 3-38)

CREAM; TOPICAL

LOPROX
 HOECHST-ROUSSEL 12M

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-38)

TABLET, CONTROLLED RELEASE; ORAL

TAVIST D
 DORSEY LABS/SANDOZ EQ 1MG BASE; 75MG

CYCLOPENTOLATE HYDROCHLORIDE (PAGE 3-44)

SOLUTION/DROPS; OPHTHALMIC

PENTOLATR
 PHARMFAIR 12M

CYCLOPHOSPHAMIDE (PAGE 3-44)

INJECTABLE; INJECTION

CYTOXAN

HEAD JOHNSON/B-M 16M/VIAL
 26M/VIAL

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)

SYRUP; ORAL

CYPROHEPTADINE HCL

AA BAY LABORATORIES 2MG/5ML

TABLET; ORAL

CYPROHEPTADINE HCL

AA ASCOT HOSP PHARMS 4MG
 /AA/ /FEDERAL PHARM LABS/ /4MG/
 AA LEMMON 4MG
 AA MD PHARMACEUTICAL 4MG

DEXAMETHASONE (PAGE 3-47)

TABLET; ORAL
DEXAMETHASONE
/BP/ /LEDERLE LABS/AM CYAN/0.25MG/
/BP/ /2.5MG/
/BP/ /ROXANE LABORATORIES 2MG/
/BP/ /WEST-WARD/ /0.75MG/

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

INJECTABLE; INJECTION
DEXAMETHASONE
AP ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML
AP EQ 10MG PHOSPHATE/ML
/AP/ DEXAMETHASONE SODIUM PHOSPHATE
/ELKINS-SINN/AHROBINS/EQ 4MG PHOSPHATE/ML/

ointment; OPHTHALMIC
DECADRON
AT MS&D/MERCK EQ 0.05% PHOSPHATE
AT DEXAIR EQ 0.05% PHOSPHATE
AT PHARMAFAIR EQ 0.05% PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
DEXAMETHASONE SODIUM PHOSPHATE
/AT/ BARNES-HIND PHARMS EQ 0.1% PHOSPHATE
/AT/ /HAURY BIOLOGICAL/ /EQ 0.1% PHOSPHATE/

SOLUTION/DROPS; OPHTHALMIC, OTIC
DECADRON
AT MS&D/MERCK EQ 0.1% PHOSPHATE
AT DEXAMETHASONE SODIUM PHOSPHATE
AT HAURY BIOLOGICAL EQ 0.1% PHOSPHATE

/DEXEROPHENTRAMINE MALEATE; PSEUDOPHEDRINE SULFATE (PAGE 3-49)

TABLET; ORAL/
/DISOPHROL/
/SCHERING/ /2MG;60MG/

TABLET; CONTROLLED RELEASE; ORAL/
/DIXON/
/SCHERING/ /6MG;120MG/

DEXTROAMPHETAMINE SULFATE (PAGE 3-49)

TABLET; ORAL
DEXTOAMPHETAMINE SULFATE
/AA/ /STANLABS/SINAK/ /END/

DEXTROSE (PAGE 3-50)

INJECTABLE; INJECTION
DEXTROSE 60%
AP AM MCGAM/AM HOSP 60GM/100MLM

DEXTROSE; POTASSIUM CHLORIDE (PAGE 3-52)

INJECTABLE; INJECTION
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC
CONTAINER
AP AM MCGAM/AM HOSP 5GM/100ML;75MG/100MLM
AP TRAVENOL LABS 5GM/100ML;75MG/100ML
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC
CONTAINER
AP AM MCGAM/AM HOSP 5GM/100ML;150MG/100MLM
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC
CONTAINER
AP AM MCGAM/AM HOSP 5GM/100ML;220MG/100MLM
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC
CONTAINER
AP TRAVENOL 5GM/100ML;224MG/100ML
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC
CONTAINER
AP AM MCGAM/AM HOSP 5GM/100ML;300MG/100MLM

DIATRIZOATE MEGUMINE (PAGE 3-54)

INJECTABLE; INJECTION
ANGIOVIST 282
AP BERLEX/SCHERING AG 60%
UROVIST MEGUMINE DIU/CI
AP BERLEX/SCHERING AG 30%
SOLUTION; URETHRAL
UROVIST CYSTO
AT BERLEX/SCHERING AG 30%
UROVIST CYSTO PEDIATRIC
AT BERLEX/SCHERING AG 30%

DIATRIZOATE MEGUMINE; DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
ANGIOVIST 292
AP BERLEX/SCHERING AG 52%82M
ANGIOVIST 370
AP BERLEX/SCHERING AG 66%102M
SOLUTION; ORAL, RECTAL
GASTROVIST
AA BERLEX/SCHERING AG 66%102M

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-58)

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
/AA/ /GENERIC PHARM/ /25MG/ /50MG/
/AA/
 LNK INTERNATIONAL 25MGH
 50MGH
/AA/ /PREMO PHARM LABS/ /25MG/ /50MG/
/AA/
 VANGARD LABS/PHM 25MGH
/AA/

ELIXIR; ORAL
DIPHENHYDRAMINE HCL
AA LIFE LABORATORIES 12.5MG/5MLM

DOPAMINE HYDROCHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION
DOPAMINE HCL
AP ABBOTT LABORATORIES 80MG/MLM

DOXYCYCLINE HYCLATE (PAGE 3-61)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
AB BARR LABORATORIES EQ 50MG BASEM
AB EQ 100MG BASEM
AB DANBURY PHARMACAL EQ 50MG BASEM
AB EQ 100MG BASEM

TABLET; ORAL
DOXYCYCLINE HYCLATE
AB BARR LABORATORIES EQ 100MG BASEM
AB DANBURY PHARMACAL EQ 100MG BASEM
AB MYLAN PHARMS EQ 100MG BASEM

DYDROGESTERONE (PAGE 3-61)

TABLET; ORAL
/BP/ /PUPHASTON/
/BP/ /ROXANE LABORATORIES/ /5MG/ /10MG/
 GYNOREST
/BP/ MEAD JOHNSON/B-H 5MG
/BP/ 10MG

ECONAZOLE NITRATE (PAGE 3-62)

CREAM; TOPICAL
 SPECTAZOLE
 ORTHO PHARMACEUTICAL 12M

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
UROVIST SODIUM 300
AP BERLEX/SCHERING AG 502M

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-56)

CAPSULE; ORAL
 TENUCAP
 MERRELL DOW/DOW CHEM 25MGH

DIETHYLSTILBESTROL (PAGE 3-56)

TABLET; ORAL
DIETHYLSTILBESTROL
> DLT > /BP/ /WEST-WARD/ /1MG/

DILTIAZEM HYDROCHLORIDE (PAGE 3-57)

TABLET; ORAL
 CARDIZEM
 MARION LABORATORIES EQ 30MG BASEM
 EQ 60MG BASEM

DIMENHYDRINATE (PAGE 3-57)

INJECTABLE; INJECTION
DIMENHYDRINATE
/AP/ /CENTRAL PHARMS/ /50MG/ML/
/SUPPOSITORY; RECTAL/
/DRUGLINE/
/SEARLE PHARMS/ /1.00MG/

DINOPROST TRIMETHAMINE (PAGE 3-59)

INJECTABLE; INJECTION
 PROSTIN F2 ALPHA
 UPJOHN
/5MG/ML/
 EQ 5MG BASE/ML

EPINEPHRINE; ETIDOCaine HYDROCHLORIDE (PAGE 3-62)

INJECTABLE; INJECTION
/DURANEST, W. EPINEPHRINE/
DURANEST

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-63)

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE
ASTRA PHARM PRODS 0.005MG/ML; 0.5%
M

ERGOLOID MESYLATES (PAGE 3-63)

CAPSULE; ORAL
HYDERGINE
SANDOZ PHARMS/SANDOZ 1MG^M

TABLET; ORAL

ERGOLOID MESYLATES
AB DANBURY PHARMACAL 1MG^M

TABLET; SUBLINGUAL

ALKERGOT
/AA/ /PRENO. PHARM. LABS/ /0.5MG/
/AA/ /LEMON/ /1MG/
AA 0.5MG
AA 1MG
H.E.A.
AA VANGARD LABS/PHM 0.5MG^M
AA 1MG^M

ERGOTAMINE TARTRATE (PAGE 3-64)

TABLET; SUBLINGUAL

ERGOMAR
FISONS 2MG^M
NIGRETTES
/ADD > AA
/ADD > AA ORGANON/AKZONA 2MG

ERYTHROMYCIN (PAGE 3-64)

OINTMENT; OPHTHALMIC
ILOTYCIN
DISTA PRODS/LILLY 5MG/GM

SOLUTION; TOPICAL

A/T/S
AT HOECHST-ROUSSEL 2%^M

TABLET, ENTERIC COATED; ORAL

ILOTYCIN
/BX/ /DISTA. PRODS/LILLY/ /500MG/
AB DISTA PRODS/LILLY 250MG

ERYTHROMYCIN ESTOLATE (PAGE 3-64)

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE
AB NATL PHARM MFG/BARRE EQ 125MG BASE/5ML^M
AB EQ 250MG BASE/5ML^M

ILOECONE

AB DISTA PRODS/LILLY EQ 125MG BASE/5ML^M
AB EQ 250MG BASE/5ML^M

ESTROGENS, ESTERIFIED (PAGE 3-67)

TABLET; ORAL

/BS/ /GLYESTERIN/
/BS/ /FIRST. TEXAS/SCHERRER/ /0.625MG/
/BS/ /1.25MG/
/BS/ /2.5MG/

ESTRONE (PAGE 3-68)

INJECTABLE; INJECTION
NATURAL ESTROGENIC SUBSTANCE-ESTRONE
BP CARTER-GLOGAU LABS 2MG/ML^M

ETHINYL ESTRADIOL; ETHINYLDIOL DIOXIDATE; FERROUS FUMARATE/ (PAGE 3-69)

/TABLET; ORAL-28/
/PENGLEN-FE-28/
/SEARLE/SEARLE PHARMS/ 0.05MG; 1MG; 2.5MG/

ETOMIDATE (PAGE 3-71)

INJECTABLE; INJECTION

AMIDATE
AP ABBOTT LABORATORIES 2MG/ML^M
HYPOCIDATE
AP JANSSEN PHARMA 2MG/ML^M

FENFLURAMINE HYDROCHLORIDE (PAGE 3-71)

TABLET, CONTROLLED RELEASE; ORAL
PONDININ
AH ROBINS 60MG^M

FLUOCINOLONE ACETONIDE (PAGE 3-72)

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

AT E FOUGERA/BYK-GULDEN 0.012M
AT 0.0252M
AT PHARMADERM/BYK-GULDEN 0.012M
AT 0.0252M

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

AT E FOUGERA/BYK-GULDEN 0.0252M
AT PHARMADERM/BYK-GULDEN 0.0252M

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT E FOUGERA/BYK-GULDEN 0.012M
AT PHARMADERM/BYK-GULDEN 0.012M

FLUOROURACIL (PAGE 3-73)

INJECTABLE; INJECTION

FLUOROURACIL

AP CARTER-GLOGAU LABS 50MG/MLM
AP MARCHAR LABORATORIES 50MG/MLM

FUROSEMIDE (PAGE 3-75)

TABLET; ORAL

FUROSEMIDE

AB PARKE-DAVIS/M-L 20MG
AB 40MG
AB SUPERPHARM 40MG

> ADD >

GENTAMICIN SULFATE (PAGE 3-76)

INJECTABLE; INJECTION

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

EQ 0.8MG BASE/MLM
TRAVENOL LABS
EQ 80MG BASE/100MLM

GONADORELIN HYDROCHLORIDE (PAGE 3-77)

INJECTABLE; INJECTION

FACITREL

AYERST LABS/AMHO
EQ 0.1MG BASE/VIALM
EQ 0.5MG BASE/VIALM

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-77)

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR

AT 0.025MG/ML; EQ 1.75MG BASE/ML;
AT 5,000 UNITS/MLM
0.025MG/ML; EQ 1.75MG BASE/ML;
10,000 UNITS/MLM

GUANABENZ ACETATE (PAGE 3-78)

TABLET; ORAL

MYTENSIN

MYETH LABS/AMHO EQ 4MG BASEM
EQ 8MG BASEM

GUANADREL SULFATE (PAGE 3-78)

TABLET; ORAL

HYLOREL

UPJOHN
10MGX
25MGX

HALOPERIDOL (PAGE 3-78)

/CONCENTRATE; ORAL/

/HALDOL/

/MCNEIL LABORATORIES//5MG/ML/

/INJECTABLE; INJECTION/

/HALDOL/

/MCNEIL LABORATORIES//5MG/ML/

HALOPERIDOL LACTATE (PAGE 3-79)

CONCENTRATE; ORAL

HALDOL

MCNEIL LABORATORIES EQ 2MG BASE/ML

INJECTABLE; INJECTION

HALDOL

MCNEIL LABORATORIES EQ 5MG BASE/ML

HEPARIN CALCIUM (PAGE 3-79)

INJECTABLE; INJECTION

CALCIPARINE

/CHOX LABORATORIES/ 25,000 UNITS/ML/
AM CRITICAL CARE/AHS 25,000 UNITS/ML

LEUCOVORIN CALCIUM (PAGE 3-98)

INJECTABLE; INJECTION
WELLCOVORIN
BURROUGHS WELLCOME

EQ 5MG BASE/MLM

LIDOCAINE (PAGE 3-99)

ointment; TOPICAL
LIDOCAINE
/AT/ /PREP/

/52/

LIDOCAINE HYDROCHLORIDE (PAGE 3-100)

INJECTABLE; INJECTION
LIDOCAINE HCL
ABBOTT LABORATORIES

102M

> ADD > AP

SOLUTION; ORAL
BAYLOCANE

AT BAY LABORATORIES

22M

SOLUTION; TOPICAL
BAYLOCANE

AT BAY LABORATORIES

42M

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE (PAGE 3-103)

INJECTABLE; INJECTION
PLASMA-LYTE A IN PLASTIC CONTAINER

TRAVENOL LABS
/ABBOTT LABORATORIES/

AP 30MG/100ML; 37MG/100ML; 568MG/100ML;
AP 526MG/100ML; 502MG/100ML

SOLUTION; IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER

/ABBOTT LABORATORIES/ 14MG/100ML; 37MG/100ML; 568MG/100ML;
/526MG/100ML; 502MG/100ML/
ABBOTT LABORATORIES 30MG/100ML; 37MG/100ML; 222MG/100ML;
526MG/100ML; 502MG/100ML

MALATHION (PAGE 3-104)

LOTION; TOPICAL
PRIODERM

PURDUE FREDERICK
0.5/M

MAPROTILINE HYDROCHLORIDE (PAGE 3-104)

TABLET; ORAL
LUDIONIL

CIBA/CIBA-GEIGY

75MG

MEPIVACAIN HYDROCHLORIDE (PAGE 3-107)

INJECTABLE; INJECTION
CARBOCANE

AP BREON LABS/STERLING 12
MEPIVACAIN HCL

AP INTL MEDICATION SYS 12M

MEPROBAMATE (PAGE 3-107)

TABLET; ORAL
MEPROBAMATE

/AA/ /LEDERLE LABS/AN-CYAN/200MG/

METHADONE HYDROCHLORIDE (PAGE 3-110)

SOLUTION; ORAL
METHADONE HCL

ROXANE LABORATORIES 10MG/5MLM

METHANTHLINE BROMIDE (PAGE 3-111)

INJECTABLE; INJECTION
/BANTHINE/

/SEARLE/SEARLE PHARMS/50MG/VIAL/

METHOCARBAMOL (PAGE 3-112)

TABLET; ORAL
METHOCARBAMOL

AA ASCOT HOSP PHARMS 500MG
AA 750MG

METHYCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL
AQUATENSEN

> DLI > /BP/ /MALLACE LABS/C-W/ 5MG
> ADD > AB /MALLACE LABS/C-W/ 5MG

METHYCLOTHIAZIDE
MYLAN PHARMS

AB 2.5MG
AB 5MG

METHYLPREDNISOLONE ACETATE (PAGE 3-115)

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

BP MAURRY BIOLOG CAL 40MG/MLM
BP 80MG/MLM

METHYLPREDNISOLONE SODIUM SUCCINATE (PAGE 3-115)

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE
INTL MEDICATION SYS EQ 40MG BASE/VIALM
EQ 125MG BASE/VIALM
EQ 500MG BASE/VIALM
EQ 1GM BASE/VIALM

> ADD > AP
> ADD > AP
> ADD > AP
> ADD > AP

METHYLTESTOSTERONE (PAGE 3-115)

CAPSULE; ORAL

METHYLTESTOSTERONE 10MG
BP HEATHER DRUG
VIRILON
/BP/ /HEATHER DRUG/ /10MG/
BP STAR PHARMACEUTICALS 10MG

TABLET; ORAL
METHYLTESTOSTERONE 10MG
BP LANNETT 25MG

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION

METRO I.V.
AP AM MCGAW/AM HOSP 500MG/100MLM

TABLET; ORAL

METRONIDAZOLE
BARR LABORATORIES 250MG
500MG
CHELSEA LABORATORIES 250MG
CORD LABORATORIES 250MG
500MG
DANBURY PHARMACAL 250MG
500MG
/LEMON/ /250MG/
METRYL
AB LEMTON 250MG

> ADD > AB
> ADD > AB
> ADD > AB
> ADD > AB
> ADD > AB
> ADD > AB
> ADD > AB
> ADD > AB

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

TABLET; ORAL

MINOCIN
LEDERLE LABS/AM CYAN EQ 50MG BASEM
EQ 100MG BASEM

METHRAMIDIN (PAGE 3-118)

PLICAMYCIN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE (PAGE 3-119)

TABLET; ORAL

TALKIN NX
WINTHROP LABS/STERL 0.5MG/EQ 50MG BASEM

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-121)

ointment; OPHTHALMIC

NEO-HYDELTRASOL
MS&D/MERCK EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE

> ADD > NETILMICIN SULFATE (PAGE 3-121)

> ADD > INJECTABLE; INJECTION

> ADD > NETROMYCIN EQ 10MG BASE/MLM
> ADD > SCHERING EQ 25MG BASE/MLM
> ADD > EQ 100MG BASE/MLM

NIACIN (PAGE 3-121)

TABLET; ORAL

NIACIN
/AA/ /GENERIC PHARM/XY/ /500MG/

NITROGLYCERIN (PAGE 3-122)

INJECTABLE; INJECTION

NITROL
AP KREHERS-URBAN 0.8MG/MLM
NETROSTAT
AP PARKE-DAVIS/M-L 0.8MG/ML

NYSTATIN (PAGE 3-123)

ointment; TOPICAL

NYSTATIN
AT BYK-GULDEN 100,000 UNITS/GMM

TABLET; ORAL

NYSTATIN
AA CHELSEA LABORATORIES 500,000 UNITS/M

oxolinic Acid (PAGE 3-125)

TABLET; ORAL

oxolinic Acid
/OTIBID/
/PARKE-DAVIS/M-L/ /750MG/

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL

OXYTETRACYCLINE HCL

/AB/ /LEDERLE LABS/AM CYN/EA 250MG BASE/

PHENYLBUTAZONE (PAGE 3-134)

CAPSULE; ORAL

PHENYLBUTAZONE

AB CHELSEA LABORATORIES 100MG

PENICILLIN G POTASSIUM (PAGE 3-128)

TABLET; ORAL

PENICILLIN G POTASSIUM/AB/ /JOHN D. COPANOS/ /100,000 UNITS/
/AB/ /JOHN D. COPANOS/ /200,000 UNITS/
/AB/ /JOHN D. COPANOS/ /250,000 UNITS/
/AB/ /JOHN D. COPANOS/ /400,000 UNITS/
/AB/ /JOHN D. COPANOS/ /500,000 UNITS/PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE/AA/ /CORP. LABORATORIES/ /10MG/
/AA/ /CORP. LABORATORIES/ /15MG/
/AA/ /REID-PROVIDENT LABS/ /15MG/
SPRX-3

AA REID-PROVIDENT LABS 35MG

X-TROZINE

AA REXAR PHARMACAL 35MG

CAPSULE, CONTROLLED RELEASE; ORAL

MELFIAT-105

BC REID-PROVIDENT LABS 105MG

SPRX-105

BC REID-PROVIDENT LABS 105MG

X-TROZINE L.A.

BC REXAR PHARMACAL 105MG

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

/AA/ /GENERIC PHARM/ /15MG/

PHENTERMINE HYDROCHLORIDE (PAGE 3-133)

CAPSULE; ORAL

PHENTERMINE HCL

> ADD > AA LANNETT 30MG

TABLET; ORAL

ADIFEX-P

AA LENTON 37.5MG

PHENTERMINE HCL

AA CAMALL 37.5MG

/AA/ /CORP. LABORATORIES/ /37.5MG/

ICRA

AA REID-PROVIDENT LABS 37.5MG

POTASSIUM CHLORIDE (PAGE 3-137)

CAPSULE, CONTROLLED RELEASE; ORAL

TIMKAP

/BC/ /BERTEL/SCHERINS/ /8MEQ/

BC CIBA/CIBA-GEIGY 8MEQ

POTASSIUM CHLORIDE; SODIUM CHLORIDE (PAGE 3-138)

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.075% IN PLASTIC

AP AM HCGAN/AM HOSP 75MG/100ML; 900MG/100ML

AP TRAVENOL LABS 75MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.15% IN PLASTIC

AP AM HCGAN/AM HOSP 150MG/100ML; 900MG/100ML

AP TRAVENOL LABS 150MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.22% IN PLASTIC

AP AM HCGAN/AM HOSP 220MG/100ML; 900MG/100ML

AP TRAVENOL LABS 220MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.224% IN PLASTIC

AP AM HCGAN/AM HOSP 224MG/100ML; 900MG/100ML

AP TRAVENOL LABS 224MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC

AP AM HCGAN/AM HOSP 300MG/100ML; 900MG/100ML

AP TRAVENOL LABS 300MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 1CMER (K) IN PLASTIC

AP AM HCGAN/AM HOSP 150MG/100ML; 900MG/100ML

AP TRAVENOL LABS 150MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 2CMER (K) IN PLASTIC

AP AM HCGAN/AM HOSP 150MG/100ML; 900MG/100ML

AP TRAVENOL LABS 150MG/100ML; 900MG/100ML

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 4CMER (K) IN PLASTIC

AP AM HCGAN/AM HOSP 300MG/100ML; 900MG/100ML

AP TRAVENOL LABS 300MG/100ML; 900MG/100ML

<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE; TRIMETHAMINE</u> (PAGE 3-138)		<u>PROCHLORPERAZINE EDISYLATE</u> (PAGE 3-144)	
INJECTABLE; INJECTION THAM-E ABBOTT LABORATORIES / 0.375MG/ML; 0.75MG/ML; 1.5MG/ML; 370MG/VIAL; 1.756G/VIAL; 3.66G/VIAL		SYRUP; ORAL CHLORPAC AA SK&F LABORATORIES EQ 5MG BASE/5ML PROCHLORPERAZINE EDISYLATE AA NATL PHARM MFG/BARRE EQ 5MG BASE/5ML	
<u>PRAZIQUNTEL</u> (PAGE 3-139)		<u>PROMETHAZINE HYDROCHLORIDE</u> (PAGE 3-145)	
TABLET; ORAL BILTRICIDE MILES PHARMS/MILES 600MG		INJECTABLE; INJECTION /EMENDIN-50/ /BP/ /CENTRAL PHARMS/ /50MG/ML/	
<u>PREDNISOLONE</u> (PAGE 3-139)		SYRUP; ORAL BAYMETHAZINE AA BAY LABORATORIES 6.25MG/5ML BAYMETHAZINE FORTIS AA BAY LABORATORIES 25MG/5ML	
CREAM; TOPICAL METI-DERM SCHERING 0.5%		TABLET; ORAL PROMETHAZINE HCL /BP/ /LEDERLE LABS/AM CYAN/25MG/ /BP/ /50MG/	
TABLET; ORAL PREDNISOLONE /BX/ /PUREPAC/KALIPHARMA/ /5MG/ BX UNIT DOSE LABS 5MG		<u>PROPANTHLINE BROMIDE</u> (PAGE 3-146)	
<u>PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM</u> (PAGE 3-140)		TABLET; ORAL PROPANTHLINE BROMIDE ASCOT HOSP PHARMS 15MG /AA/ /LEDERLE LABS/AM CYAN/15MG/ > DLT > /AA/	
SUSPENSION/DROPS; OPHTHALMIC METHYD AT SCHERING 0.52%; 10%		<u>PROPACACINE HYDROCHLORIDE</u> (PAGE 3-146)	
AT SULPHRIN AT MURO PHARMACEUTICAL 0.52%; 10%		SOLUTION/DROPS; OPHTHALMIC PROPACACINE AT PRO PHARMA/STERI-MED 0.52%	
<u>PREDNISONE</u> (PAGE 3-141)		<u>PROPOXYPHENE HYDROCHLORIDE</u> (PAGE 3-147)	
TABLET; ORAL PREDNISONE UNIT DOSE LABS 5MG BX 10MG BX 20MG		CAPSULE; ORAL PROPOXYPHENE HCL /AA/ /GENERIC PHARM/IVY/ /65MG/ /AA/ /FRENCH PHARM LABS/ /65MG/ /AA/ /LEMON /AA/ /ROXANE LABORATORIES/ /65MG/ /AA/ /ROXANE LABORATORIES/ 65MG	
<u>PROBENECID</u> (PAGE 3-142)		<u>PROCHLORPERAZINE EDISYLATE</u> (PAGE 3-144)	
TABLET; ORAL PROBENECID /AB/ /BEECHAM LABS/BEECHAM/ 500MG/		INJECTABLE; INJECTION PROCHLORPERAZINE AP ELKINS-SINN/AHROBINS EQ 5MG BASE/ML	

PROPRANOLOL HYDROCHLORIDE (PAGE 3-147)

TABLET; ORAL
 INDERAL
 AYERST LABS/AMHO

60MG
 90MG

RITODRINE HYDROCHLORIDE (PAGE 3-153)

TABLET; ORAL

YUTOPAR
 /AB/ /MERRELL, DON/ DON/ CHEM/ 10MG/
 AB AB ASTRA PHARM PRODS 10MG

PSEUDOEPHEDRINE HYDROCHLORIDE; IRIPRODILINE HYDROCHLORIDE (PAGE 3-148)

/SYRUP; ORAL/
 /ACTIFED/
 /BURROUGHS, WELLCOME/ /30MG/5ML; 2.5MG/5ML/

/TABLET; ORAL/
 /ACTIFED/
 /BURROUGHS, WELLCOME/ /60MG; 2.5MG/

TABLET; ORAL
 TRIPRODRINE
 DANBURY PHARMACAL

60MG; 2.5MG

PIRITOXINE HYDROCHLORIDE (PAGE 3-149)

INJECTABLE; INJECTION
 PYRITOXINE HCL
 MAURRY BIOLOGICAL

100MG/ML

QUINIDINE GLUCONATE (PAGE 3-150)

TABLET, CONTROLLED RELEASE; ORAL
 QUINIDINE GLUCONATE

AB CHELSEA LABORATORIES 324MG
 AB DANBURY PHARMACAL 324MG

RESERPINE (PAGE 3-151)

TABLET; ORAL
 RESERPINE

/BP/ /GENERIC, PHARM, TAY/ /0.25MG/
 /BP/ /LEDERLE, LABS/ AN CYAN/ 0.25MG/
 /BP/ TABLICALS /0.1MG/

RITODRINE HYDROCHLORIDE (PAGE 3-153)

INJECTABLE; INJECTION

YUTOPAR
 /AB/ /MERRELL, DON/ DON/ CHEM/ 10MG/ML/
 AB AB ASTRA PHARM PRODS 10MG/ML

SECRETIN (PAGE 3-154)

INJECTABLE; INJECTION

SECRETIN-KABI
 /KABI GROUP/
 KABIVITRUM

/75CU/VIAL/
 75CU/VIAL

SISCHONIN SULFATE (PAGE 3-155)

/INJECTABLE; INJECTION/
 /SISCHONIN/

/50MG/ML/

SODIUM CELLULOSE PHOSPHATE (PAGE 3-155)

POWDER; ORAL

CALCIBIND
 UNIV TEXAS/HSC

2.5GM/PACKET

SODIUM CHLORIDE (PAGE 3-155)

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 ABBOTT LABORATORIES

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 ABBOTT LABORATORIES

2MG/ML

AP

SODIUM POLYSTYRENE SULFONATE (PAGE 3-158)

SUSPENSION; ORAL, RECTAL

SPS
 CAROLINA MED PRODS

15GM/60ML

SOYBEAN OIL (PAGE 3-159)

INJECTABLE; INJECTION

INTRALIPID 20%
 CUTTER-VITRUM 20%
 TRAVANILSON 20%
 TRAVENOL LABS 20%

> ADD > AP

> ADD > AP

> ADD > AP

SPIRONOLACTONE (PAGE 3-159)

TABLET; ORAL

SPIRONOLACTONE

AB ASCOT HOSP PHARMS 25MG
AB PARKE-DAVIS/M-L 25MG

SUCCINYLCHOLINE CHLORIDE (PAGE 3-159)

INJECTABLE; INJECTION

SUCCININ

/AP/ ER SQUIBB AND SONS /500MG/ML/

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA (PAGE 3-160)

CREAM; VAGINAL

SULNAC

AI NHC LABORATORIES 3.72;2.862;3.422;0.642M
AI TRIPLE SULFA 3.72;2.862;3.422;0.642M
AI CLAY-PARK LABS

SULFACETAMIDE SODIUM (PAGE 3-160)

OINTMENT; OPHTHALMIC

SULFAIR 10

AI PHARMAFAIR 102M

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

AI PHARMAFAIR 102M

SULTEN-10

> ADD > AI MURO PHARMACEUTICAL 102M

SULFAMETER (PAGE 3-161)

TABLET; ORAL

SULFA

/AP/ BERLEX/SCHERING/ /500MG/

SULFAMETHOXAZOLE (PAGE 3-161)

TABLET; ORAL

SULFAMETHOXAZOLE

AB ASCOT HOSP PHARMS 500MG

SULFAMETHOXAZOLE; TRIMETHOPRIM (PAGE 3-161)

SUSPENSION; ORAL

SMZ-TMP

AB BIOCRAFT LABS 200MG/5ML;40MG/5ML
AB SULFATRIN
AB NATL PHARM MFG/BARRE 200MG/5ML;40MG/5ML
AB SULFATRIN PEDIATRIC
AB NATL PHARM MFG/BARRE 200MG/5ML;40MG/5ML

SULFASALAZINE (PAGE 3-162)

TABLET; ORAL

SULFASALAZINE

/BP/ /CHELSEA LABORATORIES/500MG/
AB CHELSEA LABORATORIES 500MG

SULFINPYRAZONE (PAGE 3-162)

CAPSULE; ORAL

ANTURANE

AB CIBA/CIBA-GEIGY 200MG
AB SULFINPYRAZONE
AB BARR LABORATORIES 200MG
AB ZENITH LABORATORIES 200MG

TABLET; ORAL

SULFINPYRAZONE

AB BARR LABORATORIES 100MG

SULFISOXAZOLE (PAGE 3-162)

TABLET; ORAL

SULFISOXAZOLE

/BP/ /FRENCH PHARM LABS/ /500MG/
BP LEMMON 500MG

TECHNETIUM, TC-99M, MEDRONATE KIT (PAGE 3-164)

INJECTABLE; INJECTION

AMERSCAN

AB AMERSHAM/RADIOCHEM N/A

TECHNETIUM, TC-99M, PENETATE KIT (PAGE 3-165)

INJECTABLE; INJECTION

/CINTICHEN/TECHNETIUM-99M-DTPA/
DTPA

TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)

INJECTABLE; INJECTION
TECHNETIUM TC 99M SULFUR COLLOID
/SYNCOB, INC./ /4ML/

TRETINOIN (PAGE 3-172)

GEL; TOPICAL
RETIN-A
ORTHO PHARMACEUTICAL/0.05%/

TETRACYCLINE (PAGE 3-166)

> DLT >
> DLT > /AB/ SYRUP; ORAL
/ROBITEL/
/AM. ROBINS/ /EQ 125MG SOL/5ML/
TETRACYCLINE /EQ 125MG SOL/5ML/
/NEST-HARD/

THALLOUS CHLORIDE, TL-201 (PAGE 3-168)

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
AP AMERSHAM/RADIOCHEM 1MCI/MLM

THEOPHYLLINE (PAGE 3-168)

SYRUP; ORAL
AA AQUAPHYLLIN 80MG/15MLM
/SLO-PHYLLIN-80/
/POONER, LABORATORIES/ 80MG/15ML/
AA WILLIAM H RORER 80MG/15ML

TABLET; ORAL
SLO-PHYLLIN
/POONER, LABORATORIES/ 100MG/
/PO/ 200MG
BD WILLIAM H RORER 100MG
BD 200MG

TABLET, CONTROLLED RELEASE; ORAL
THEOCONTIN
PURDUE FREDERICK 400MG
THEOCHRON
BC FOREST LABORATORIES 300MG

THIAMINE HYDROCHLORIDE (PAGE 3-169)

INJECTABLE; INJECTION
THIAMINE HCL
AP MAURRY BIOLOGICAL 100MG/MLM

TRIAMCINOLONE ACETONIDE (PAGE 3-173)

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
PHARMAFAIR 0.025%
AT 0.1%
AT 0.5%
AT

LOTION; TOPICAL

KEVALOS
AT ER SQUIBB AND SONS 0.025%
AT 0.1%
TRIAMCINOLONE ACETONIDE
AT NATL PHARM MFG/BARRE 0.025%
AT 0.1%

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE
AT BYK-GULDEN 0.025%
AT THAMES PHARMACAL 0.1%

TRIAZOLAM (PAGE 3-174)

TABLET; ORAL
HALCION
UPJOHN 0.25MG
0.5MG

TRICHLORMETHIAZIDE (PAGE 3-174)

TABLET; ORAL
TRICHLORMETHIAZIDE
/BP/ /PRENO PHARM LABS/ /4MG/
BP LEMMON 4MG

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-175)

CONCENTRATE; ORAL
/TRIAZINE/
IFP
TABLET; ORAL
TRIFLUOPERAZINE HCL
ZENITH LABORATORIES
AB EQ 1MG BASEM
AB EQ 2MG BASEM
AB EQ 5MG BASEM
AB EQ 10MG BASEM

TRIMETHOBENZAMIDE HYDROCHLORIDE (PAGE 3-176)INJECTABLE; INJECTIONTIGANAP BEECHAM LABS/BEECHAM 100MG/MLTRIMETHOBENZAMIDE HCLAP CARTER-GLOGAU LABS 100MG/MLTRIMETHOPRIM (PAGE 3-176)TABLET; ORALPROLOPRIMAB BURROUGHS WELLCOME 200MGTRIMPEX 200AB HOFFMANN-LA ROCHE 200MGTRIMIPRAMINE MALEATE (PAGE 3-176)CAPSULE; ORALSURMONTIL

IVES LABS/AMHO EQ 100MG BASE

TRIPROLIDINE HYDROCHLORIDE (PAGE 3-177)SYRUP; ORALBAYDYLAA BAY LABORATORIES 1.25MG/5MLTROMETHAMINE (PAGE 3-177)INJECTABLE; INJECTIONTHAMABBOTT LABORATORIES 1/4MG/ML
3.6GM/100MLTROPICAMIDE (PAGE 3-178)SOLUTION/DROPS; OPHTHALMICHYDRIACYLAT ALCON LABORATORIES 12TROPICAMIDEAT PRO PHARMA/STERI-MED 12VITAMIN A (PAGE 3-179)CAPSULE; ORALVITAMIN A/AA/ FREDERICK, ASSOC./PEACH ED 50,000 UNITS/BASEVITAMIN A PALMITATE (PAGE 3-179)CAPSULE; ORALBERN-A-CAPS/AA/ FREDERICK, ASSOC./PEACH ED 50,000 UNITS/BASEHARFARIN SODIUM (PAGE 3-180)TABLET; ORALATHROMBIN/BD/ FREDERICK, ASSOC./PEACH 5MG//BD/ FREDERICK, ASSOC./PEACH 10MG/BX PURDUE FREDERICK 5MGBX PURDUE FREDERICK 10MGCUMADIN/BD/ FREDERICK, ASSOC./PEACH 2MG//BD/ FREDERICK, ASSOC./PEACH 2.5MG//BD/ FREDERICK, ASSOC./PEACH 5MG//BD/ FREDERICK, ASSOC./PEACH 7.5MG//BD/ FREDERICK, ASSOC./PEACH 10MG/BX ENDO LABS/DUPONT 2MGBX ENDO LABS/DUPONT 2.5MGBX ENDO LABS/DUPONT 5MGBX ENDO LABS/DUPONT 7.5MGBX ENDO LABS/DUPONT 10MGPANMARFIN/BD/ ABBOTT LABORATORIES 2MG//BD/ ABBOTT LABORATORIES 2.5MG//BD/ ABBOTT LABORATORIES 5MG//BD/ ABBOTT LABORATORIES 7.5MG//BD/ ABBOTT LABORATORIES 10MG/BX ABBOTT LABORATORIES 2MGBX ABBOTT LABORATORIES 2.5MGBX ABBOTT LABORATORIES 5MGBX ABBOTT LABORATORIES 7.5MGBX ABBOTT LABORATORIES 10MGHARFARIN SODIUMBX BOLAR PHARMACEUTICAL 2MGBX BOLAR PHARMACEUTICAL 2.5MGBX BOLAR PHARMACEUTICAL 5MGBX BOLAR PHARMACEUTICAL 7.5MGBX BOLAR PHARMACEUTICAL 10MGWATER FOR INJECTION, STERILE (PAGE 3-180)LIQUID; N/ABACTERIOSTATIC WATER IN PLASTIC CONTAINER

ABBOTT LABORATORIES 100%

XENON, XE-127 (PAGE 3-181)GAS; INHALATION

XENON XE 127

MALLINCKRODT

5MCI/VIAL

10MCI/VIAL

> DLT > /ZONEPIRAC SODIUM/ (PAGE 3-181)
 > DLT > /TABLETS, ORAL/
 > DLT > /ZONAX/
 > DLT > /NORTEL LABORATORIES//EQ LOGGING BASE/

DESI PENDING LIST

CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '82 - FEBRUARY '83

CURRENT STATUS - INEFFECTIVE/BETAOLANE/ /PURDUE FRÉDÉRICK/
/POLYDENE-IODINE/DIPYRIDAMOLE /PRENO PHARM LABS/
LEMON/NEOMYCIN SULFATE-HYDROCORTISONE/ /BYK-GULDEN/
/HYDROCORTISONE; NEOMYCIN SULFATE//PATHILON/ /LEDERLE LABS/AM CYAN/
/TRIDINEXETHYL CHLORIDE//PATHILON W/ PHENOBARBITAL/ /LEDERLE LABS/AM CYAN/
/PHENOBARBITAL; TRIDINEXETHYL CHLORIDE/CURRENT STATUS - 'EXEMPT' (COURT ORDER)/BETOOLANE/ /MERRELL DOWNDOM CHEN/
/DEXPANTHENEOL; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE;/
/RIBOFLAVIN; THIAMINE HYDROCHLORIDE/BUTIBEL /MCNEIL LABORATORIES/
MALLACE LABS/C-MDIPYRIDAMOLE ASCOT HOSP PHARMS
DIPYRIDAMOLEDIPYRIDAMOLE HALSEY DRUG
DIPYRIDAMOLEDIPYRIDAMOLE /PHARMADINE LABS/
CHELSEA LABORATORIESDIPYRIDAMOLE SUPERPHARM
DIPYRIDAMOLE/FOLBESYN/ /LEDERLE LABS/AM CYAN/
/ASCORBIC ACID; FOLIC ACID; NIACINAMIDE;/
/PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; SODIUM PANTOTHENATE;/
/THIAMINE HYDROCHLORIDE/HYBEPHEN BEECHAM LABS/BEECHAM
ATROPINE SULFATE; HYOSCYAMINE SULFATE; PHENOBARBITAL;
SCOPOLAMINE HYDROBROMIDEISOSORBIDE DINITRATE INWOOD LABS/FOREST
ISOSORBIDE DINITRATEISOSORBIDE DINITRATE UNIT DOSE LABS
ISOSORBIDE DINITRATEMETHANDROSTENOLONE
METHANDROSTENOLONE> ADD > LEMMON
> ADD > NANDROLONE DECANOATE
NANDROLONE DECANOATENITRO-TIME TIME-CAP LABS
NITROGLYCERINNITROBON INWOOD LABS/FOREST
NITROGLYCERINNITROGLYCERIN VITARINE/WEST CHEM
NITROGLYCERINNITROSTAT PARKE-DAVIS/W-L
NITROGLYCERINPENTAERYTHRITOL TETRANITRATE INWOOD LABS/FOREST
PENTAERYTHRITOL TETRANITRATEPENTRASSPAN VITARINE/WEST CHEM
PENTAERYTHRITOL TETRANITRATETRANSDERM-NITRO 10 /ALZA/
CIBA/CIBA-GEIGYTRANSDERM-NITRO 2.5 /ALZA/
CIBA/CIBA-GEIGYTRANSDERM-NITRO 5 /ALZA/
CIBA/CIBA-GEIGY/VI-SYNERGY/ /EISONS/
/ASCORBIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN;/
/THIAMINE; TOCOPHEROLS; VITAMIN A; VITAMIN D/

UNIVERSITY OF MICHIGAN



3 9015 07293 3073